Skip to main
BIO

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories (BIO) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Rad Laboratories is a leading provider of products and solutions for the clinical diagnostics and life sciences markets. The company's diverse geographic presence and ownership stake in Sartorius, a lab and bioprocessing supplier, provide strong growth potential in the future. Bio-Rad's forecasted sales decline in 2026 does not require an assumption of improving end-market conditions, but rather lapping specific, idiosyncratic headwinds, making it a favorable investment option. Additionally, the company's focus on restructuring and investment in sustainability aligns with positive health outcomes, further strengthening its long-term potential.

Bears say

Bio-Rad Laboratories is facing fundamental headwinds but demonstrates compelling asset value, with its 33% ownership stake in Sartorius likely to increase in optionality following the termination of the Sartorius Trust in mid-2028. One major concern is the company's corporate governance, as the Schwartz family maintains majority ownership and control of the company, potentially leading to misalignment of interests with other shareholders. While Bio-Rad has announced sustainability goals and seeks director competence in sustainability, its integration of sustainability considerations into its strategy is limited. However, the company's core business, which supports disease prevention and diagnostics, is inherently aligned with positive health outcomes. Despite near-term challenges impacting sales growth, Bio-Rad is expected to recover in 2027, as specific headwinds (such as process chromatography and conflict in the Middle East) are expected to be resolved.

Bio-Rad Laboratories (BIO) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Rad Laboratories (BIO) Forecast

Analysts have given Bio-Rad Laboratories (BIO) a Hold based on their latest research and market trends.

According to 3 analysts, Bio-Rad Laboratories (BIO) has a Hold consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $350, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $350, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Rad Laboratories (BIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.